Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALPL | P05186 | 1/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | ALPG | P10696 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10300184 | 0.85 | KMT2A (0.59) | KMT2AALPLALPIALPGPOLB | |
| SCHEMBL3002789 | 0.81 | VCAM1 (0.60) | KMT2AALPLALPIALPGPOLB | |
| SCHEMBL17174231 | 0.81 | KDM4E (0.62) | KMT2AALPLALPIALPGPOLB | |
| SCHEMBL30993876 | 0.79 | ACLY (0.45) | KMT2AALPLALPIALPGPOLB | |
| SCHEMBL2997647 | 0.79 | ACLY (0.45) | KMT2AALPLALPIALPGPOLB | |
| SCHEMBL10186895 | 0.77 | HPGD (0.61) | KMT2APOLBLMNAMCOLN3HPGD | |
| SCHEMBL2999024 | 0.77 | KMT2A (0.52) | KMT2AALPLALPIALPGPOLB | |
| SCHEMBL13577043 | 0.74 | HPGD (0.50) | KMT2AALPLALPIALPGPOLB | |
| SCHEMBL18578297 | 0.74 | MAPT (0.60) | KMT2APOLBMAPTLMNASMN1; SMN2 | |
| SCHEMBL19018986 | 0.73 | HPGD (0.59) | HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507536-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130040975-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8263588-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100184741-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2008124614-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040975-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | KMT2A 1562/4885ALPL 3548/4885ALPI 2377/4885 |
| US-20100184741-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | KMT2A 1562/4885ALPL 3548/4885ALPI 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.